Avalo Therapeutics (AVTX) Operating Expenses (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Operating Expenses came in at $20.9 million in Q1 2026, up 42.48% YoY from $14.7 million in Q1 2025, and up 5.56% on a QoQ basis from $19.8 million in Q4 2025.
Avalo Therapeutics (AVTX) Operating Expenses (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Operating Expenses data on file, last reported at $20.9 million in Q1 2026.
- Quarterly Operating Expenses rose 42.48% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.2 million (up 55.76% YoY) and the FY2025 annual result came in at $73.0 million, up 5.85% from the prior year.
- Operating Expenses advanced to $20.9 million in Q1 2026, from $19.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $32.8 million in Q1 2024 to a low of $4.0 million in Q3 2023.
- A 5-year average of $14.6 million and a median of $13.1 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses tumbled 63.28% — and 2024, when it surged 253.59%.
- Tracing AVTX's Operating Expenses over 5 years: stood at $9.8 million in 2022, then dropped by 15.61% to $8.2 million in 2023, then surged by 64.09% to $13.5 million in 2024, then jumped by 46.64% to $19.8 million in 2025, then rose by 5.56% to $20.9 million in 2026.
- The last three Operating Expenses figures came in at $20.9 million (Q1 2026), $19.8 million (Q4 2025), and $19.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 31.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.52 Mn |
| Mar 31, 2026 | 20.90 Mn |
| Dec 31, 2025 | 19.80 Mn |
| Sep 30, 2025 | 19.20 Mn |
| Jun 30, 2025 | 19.32 Mn |
| Mar 31, 2025 | 14.67 Mn |
| Dec 31, 2024 | 13.50 Mn |
| Sep 30, 2024 | 13.11 Mn |
| Jun 30, 2024 | 9.58 Mn |
| Mar 31, 2024 | 32.77 Mn |
| Dec 31, 2023 | 8.23 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | 7.79 Mn |
| Mar 31, 2023 | 9.27 Mn |
| Dec 31, 2022 | 9.75 Mn |
| Sep 30, 2022 | 10.85 Mn |
| Jun 30, 2022 | 12.86 Mn |
| Mar 31, 2022 | 22.03 Mn |
| Dec 31, 2021 | 18.18 Mn |
| Sep 30, 2021 | 17.81 Mn |